Provided are quinoxaline derivative compounds of the general formula (I) where the variables are as described in the specification. Examples of the compounds are 3-(1,2,3,4-Tetrahydroquinolin-1(2H)-yl)-2-(4-fluorophenyl)quinoxaline-6-carboxylic acid, 2-(5-Fluoro-1-benzofuran-2-yl)-3-(6-methoxy-1,2,3,4-tetrahydroquinolin-1-yl)quinoxaline-6-carboxylic acid and 3-[2H,5H,6H,7H,8H-[1,3]Dioxolo[4,5-g]quinolin-5-yl]-2-(4-fluorophenyl)quinoxaline-6-carboxylic acid. The compounds are inhibitors of PAS kinase (PASK). The compounds may be useful in the treatment of cancer or metabolic diseases such as diabetes or hyperlipidemia.
